AZ’ Fasenra gets US nod for eosinophilic asthma
AstraZeneca | November 15, 2017
AstraZeneca’s biologic Fasenra has picked up its first global approval in the US as a treatment for severe, eosinophilic asthma, a difficult to treat a form of the condition.